Veltassa(patiromer)
Veltassa (patiromer) is a small molecule pharmaceutical. Patiromer was first approved as Veltassa on 2015-10-21. It is used to treat hyperkalemia in the USA. It has been approved in Europe to treat hyperkalemia.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nutritional and metabolic diseases | D009750 |
Trade Name
FDA
EMA
Veltassa
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Patiromer sorbitex calcium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| VELTASSA | Vifor | N-205739 RX | 2015-10-21 | 3 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| veltassa | New Drug Application | 2020-11-30 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hyperkalemia | HP_0002153 | D006947 | E87.5 |
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Patiromer Sorbitex Calcium, Veltassa, Vifor Pharma | |||
| 9492476 | 2033-10-08 | U-1766 | |
| 9925212 | 2033-10-08 | U-1766 | |
| 11123363 | 2033-10-08 | U-1766 | |
| 8337824 | 2030-05-29 | DP | U-1766 |
| 8147873 | 2028-06-20 | DP | |
| 8282913 | 2027-05-29 | DP | |
| 8216560 | 2027-03-14 | U-1766 | |
| 7556799 | 2025-02-27 | U-1766 | |
| 8287847 | 2024-03-30 | U-1766 | |
| 8475780 | 2024-03-30 | U-1766 | |
| 8778324 | 2024-03-30 | U-1766 | |
| 8889115 | 2024-03-30 | U-1766 | |
| 10485821 | 2024-03-30 | U-1766 | |
HCPCS
No data
Clinical
Clinical Trials
25 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hyperkalemia | D006947 | HP_0002153 | E87.5 | — | 7 | 3 | 7 | — | 17 |
| Chronic renal insufficiency | D051436 | N18 | — | 1 | 2 | 1 | 1 | 5 | |
| Heart failure | D006333 | EFO_0003144 | I50 | — | 2 | — | 1 | 1 | 4 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | 1 | — | 2 | — | 3 |
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | — | 2 | — | — | — | 2 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | PATIROMER |
| INN | patiromer calcium |
| Description | Patiromer, sold under the brand name Veltassa, is a medication used to treat high blood potassium. It is taken by mouth. It works by binding potassium in the gut.
|
| Classification | Small molecule |
| Drug class | polymers; antihyperlipidemic, thyromimetic derivatives |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 1260643-52-4 |
| RxCUI | 1716203 |
| ChEMBL ID | CHEMBL2107875 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB09263 |
| UNII ID | 7T97I3787N (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 525 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
192 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more